Inactive Instrument

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

January 08, 2024 at 08:30 am EST

SomaLogic, Inc. provided revenue guidance for fourth quarter and full year 2023. For the quarter the company expects fourth quarter 2023 revenue of approximately $23 million.

For the year, the company expects revenue of approximately $86 million.

Latest news about Standard BioTools Inc.

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	Jan. 10	CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	Jan. 10	CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	Jan. 08	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Standard BioTools Says Merger With SomaLogic Completed	Jan. 05	MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	Jan. 05	MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	Jan. 05	CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	Jan. 04	CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders	Jan. 04	CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery	Jan. 03	CI
Madryn Asset Provides Information to the Shareholders	Jan. 03	CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI

Chart Standard BioTools Inc.

Duration

Period

More charts

Company Profile

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research